Biotech startup grabs $27M launch round to pursue an R&D path blazed at Harvard and Boston Children’s
For the past 8 years or so Bruce Bean and Clifford Woolf at Harvard and Boston Children’s have been laboring in the lab to demonstrate how you could inhibit pain and itch signaling in a targeted set of neurons. And now a VC syndicate has assembled a team to take it into the clinic to see how it can perform among humans, handing them a $27 million launch round.
“We run a little virtual,” Nocion Therapeutics CEO Richard Batycky tells me. Right now that means 5 people on the full-time team, with plans to grow eventually to a lean-and-mean 15.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.